Budd–Chiari syndrome

Budd–Chiari syndrome is a very rare condition, affecting one in a

Budd–Chiari syndrome
million adults.[1] The condition is caused by occlusion of the hepatic
veins that drain the liver. It presents with the classical triad of
abdominal pain, ascites, and liver enlargement. The formation of a
blood clot within the hepatic veins can lead to Budd–Chiari syndrome.
The syndrome can be fulminant, acute, chronic, or asymptomatic.

Contents
Signs and symptoms
Causes
Pathophysiology
Diagnosis Budd–Chiari syndrome secondary to cancer,
Treatment note clot in the inferior vena cava and the
Prognosis metastasis in the liver
Eponym Classification and external resources
References Specialty hepatology
External links
Patient UK Budd–Chiari syndrome

Signs and symptoms

The acute syndrome presents with rapidly progressive severe upper abdominal pain, yellow discoloration of the skin and whites of
the eyes, liver enlargement, enlargement of the spleen, fluid accumulation within the peritoneal cavity, elevated liver enzymes, and
eventually encephalopathy. The fulminant syndrome presents early with encephalopathy and ascites. Liver cell death and severe
lactic acidosis may be present as well. Caudate lobe enlargement is often present. The majority of patients have a slower-onset form
of Budd–Chiari syndrome. This can be painless. A system of venous collaterals may form around the occlusion which may be seen
on imaging as a "spider's web". Patients may progress tocirrhosis and show the signs ofliver failure.

On the other hand, incidental finding of a silent, asymptomatic form may not be a cause for concern.

Causes
[2][3][4][5][6][7][8][9]
The cause can be found in more than 80% of patients.

Primary Budd–Chiari syndrome(75%): thrombosis of the hepatic vein

Hepatic vein thrombosis is associated with the following in decreasing order of frequency:

1. Polycythemia Rubra Vera

2. Pregnancy
3. Postpartum state
4. Use of oral contraceptives
5. Paroxysmal nocturnal hemoglobinuria
6. Hepatocellular carcinoma
7. Lupus anticoagulants
 Secondary Budd–Chiari syndrome(25%): compression of the hepatic vein by an outside structure (e.g. atumor)
Budd–Chiari syndrome is also seen intuberculosis, congenital venous webs and occasionally ininferior vena caval stenosis.

Often, the patient is known to have a tendency towards thrombosis, although Budd–Chiari syndrome can also be the first symptom of
such a tendency. Examples of genetic tendencies include protein C deficiency, protein S deficiency, the Factor V Leiden mutation,
hereditary anti-thrombin deficiency and prothrombin mutation G20210A.[10] An important non-genetic risk factor is the use of
estrogen-containing (combined) forms of hormonal contraception. Other risk factors include the antiphospholipid syndrome,
aspergillosis, Behçet's disease, dacarbazine, pregnancy, and trauma.

Many patients have Budd–Chiari syndrome as a complication of polycythemia vera (myeloproliferative disease of red blood
cells).[11] People who have paroxysmal nocturnal hemoglobinuria (PNH) appear to be especially at risk for Budd–Chiari syndrome,
more than other forms ofthrombophilia: up to 39% develop venous thromboses[12] and 12% may acquire Budd-Chiari.[13]

A related condition is veno-occlusive disease, which occurs in recipients of bone marrow transplants as a complication of their
medication. Although its mechanism is similar
, it is not considered a form of Budd–Chiari syndrom
e.

Other toxicologic causes of veno-occlusive disease include plant & herbal sources of pyrrolizidine alkaloids such as Borage, Boneset,
Coltsfoot, T'u-san-chi, Comfrey, Heliotrope (sunflower seeds), Gordolobo, Germander
, and Chaparral.

Pathophysiology
Any obstruction of the venous vasculature of the liver is referred to as Budd–Chiari
syndrome, from the venules to the right atrium. This leads to increased portal vein
and hepatic sinusoid pressures as the blood flow stagnates. The increased portal
pressure causes increased filtration of vascular fluid with the formation of ascites in
the abdomen and collateral venous flow through alternative veins leading to
esophageal, gastric and rectal varices. Obstruction also causes centrilobular necrosis
and peripheral lobule fatty change due to ischemia. If this condition persists
chronically what is known as nutmeg liver will develop. Renal failure may occur,
perhaps due to the body sensing an "underfill" state and subsequent activation of the
renin-angiotensin pathways and excess sodium retention.

Diagnosis
Posterior abdominal wall, after
When Budd–Chiari syndrome is suspected, measurements are made of liver enzyme
removal of the peritoneum, showing
levels and other organ markers (creatinine, urea, electrolytes, LDH). kidneys, suprarenal capsules, and
great vessels. (Hepatic veins labeled
Budd–Chiari syndrome is most commonly diagnosed using ultrasound studies of the at center top.)
abdomen and retrograde angiography. Ultrasound may show obliteration of hepatic
veins, thrombosis or stenosis, spiderweb vessels, large collateral vessels, or a
hyperechoic cord replacing a normal vein. Computed tomography (CT) or magnetic resonance imaging (MRI) is sometimes
employed although these methods are generally not as sensitive. Liver biopsy is nonspecific but sometimes necessary to differentiate
between Budd–Chiari syndrome and other causes of hepatomegaly and ascites, such as galactosemia or Reye's syndrome. Evaluation
for a JAK2 V617F mutation is recommended.

Treatment
A minority of patients can be treated medically with sodium restriction, diuretics to control ascites, anticoagulants such as heparin
and warfarin, and general symptomatic management. The majority of patients require further intervention. Milder forms of Budd–
Chiari may be treated with surgical shunts to divert blood flow around the obstruction or the liver itself. Shunts must be placed early
after diagnosis for best results.[14] The TIPS is similar to a surgical shunt: it accomplishes the same goal but has a lower procedure-
related mortality—a factor that has led to a growth in its popularity. If all the hepatic veins are blocked, the portal vein can be
approached via the intrahepatic part of inferior vena cava, a procedure called DIPS (direct intrahepatic portocaval shunt). Patients
with stenosis or vena caval obstruction may benefit from angioplasty.[15] Limited studies on thrombolysis with direct infusion of
urokinase and tissue plasminogen activatorinto the obstructed vein have shown moderate success in treating Budd–Chiari syndrome;
however, it is not routinely attempted.

Liver transplantation is an effective treatment for Budd–Chiari. It is generally reserved for patients with fulminant liver failure,
failure of shunts or progression of cirrhosis that reduces the life expectancy to 1 year.[16] Long-term survival after transplantation
ranges from 69–87%. The most common complications of transplant include rejection, arterial or venous thromboses and bleeding
due to anticoagulation. Up to 10% of patients may have a recurrence of Budd–Chiari syndrome after the transplant.

Prognosis
Several studies have attempted to predict the survival of patients with Budd–Chiari syndrome. In general, nearly 2/3 of patients with
Budd–Chiari are alive at 10 years. [14] Important negative prognostic indicators include ascites, encephalopathy, elevated Child-Pugh
scores, elevated prothrombin time, and altered serum levels of various substances (sodium, creatinine, albumin, and bilirubin).
Survival is also highly dependent on the underlying cause of the Budd–Chiari syndrome. For example, a patient with an underlying
myeloproliferative disordermay progress to acute leukemia, independently of Budd–Chiari syndrome.

Eponym
It is named after George Budd,[17][18] a British physician, andHans Chiari,[19] an Austrian pathologist.

References
1. Rajani R, Melin T, Björnsson E, Broomé U, Sangfelt P, Danielsson A, Gustavsson A, Grip O, Svensson H, Lööf L,
Wallerstedt S, Almer SH (Feb 2009)."Budd–Chiari syndrome in Sweden: epidemiology , clinical characteristics and
survival - an 18-year experience"(http://www3.interscience.wiley.com/journal/121372822/abstract). Liver
International. 29 (2): 253–9. doi:10.1111/j.1478-3231.2008.01838.x(https://doi.org/10.1111%2Fj.1478-3231.2008.01
838.x). PMID 18694401 (https://www.ncbi.nlm.nih.gov/pubmed/18694401).
2. "Etiology, management, and outcome of the Budd–Chiari syndrome".
3. "Hepatic vein thrombosis (Budd–Chiari syndrome)".
4. "The Budd–Chiari syndrome: a review".
5. "Budd–Chiari syndrome: long-term survival and factors af
fecting mortality".
6. "Budd–Chiari Syndrome: clinical patterns and therapy".
7. "Budd–Chiari syndrome: etiology, diagnosis and management".
8. "Case records of the Massachusetts General Hospital. W
eekly clinicopathological exercises. Case 51-1987.
Progressive abdominal distention in a 51-year-old woman with polycythemia vera".
9. "Hepatic outflow obstruction (Budd–Chiari syndrome). Experience with 177 patients and a review of the literature".
10. Podnos YD, Cooke J, Ginther G, Ping J, Chapman D, Newman RS, Imagawa DK (Aug 2003). "Prothrombin Mutation
G20210A as a Cause of Budd–Chiari Syndrome"(http://www.turner-white.com/pdf/hp_aug03_budd.pdf) (PDF).
Hospital Physician. 39 (8): 41–4.
11. Patel RK, Lea NC, Heneghan MA,et al. (Jun 2006). "Prevalence of the activating JAK2 tyrosine kinase mutation
V617F in the Budd–Chiari syndrome".Gastroenterology. 130 (7): 2031–8. doi:10.1053/j.gastro.2006.04.008(https://
doi.org/10.1053%2Fj.gastro.2006.04.008). PMID 16762626 (https://www.ncbi.nlm.nih.gov/pubmed/16762626).
12. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV (Nov 1995)."Natural history of paroxysmal nocturnal
hemoglobinuria" (http://content.nejm.org/cgi/pmidlookup?view=short&pmid=7566002&promo=ONFLNS19) . N Engl J
Med. 333 (19): 1253–8. doi:10.1056/NEJM199511093331904(https://doi.org/10.1056%2FNEJM199511093331904) .
PMID 7566002 (https://www.ncbi.nlm.nih.gov/pubmed/7566002).
13. Socié G, Mary JY, de Gramont A, et al. (Aug 1996). "Paroxysmal nocturnal haemoglobinuria: long-term follow-up and
prognostic factors. French Society of Haematology"(http://linkinghub.elsevier.com/retrieve/pii/S0140673695123601).
Lancet. 348 (9027): 573–7. doi:10.1016/S0140-6736(95)12360-1(https://doi.org/10.1016%2FS0140-6736%2895%2
912360-1). PMID 8774569 (https://www.ncbi.nlm.nih.gov/pubmed/8774569).
14. Murad SD, Valla DC, de Groen PC,et al. (Feb 2004). "Determinants of survival and the ef
fect of portosystemic
shunting in patients with Budd–Chiari syndrome".Hepatology. 39 (2): 500–8. doi:10.1002/hep.20064 (https://doi.org/
10.1002%2Fhep.20064). PMID 14768004 (https://www.ncbi.nlm.nih.gov/pubmed/14768004).
15. Fisher NC, McCafferty I, Dolapci M, et al. (Apr 1999). "Managing Budd–Chiari syndrome: a retrospective review of
percutaneous hepatic vein angioplasty and surgical shunting"(http://gut.bmj.com/cgi/pmidlookup?view=long&pmid=1
0075967). Gut. 44 (4): 568–74. doi:10.1136/gut.44.4.568 (https://doi.org/10.1136%2Fgut.44.4.568). PMC 1727471
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1727471). PMID 10075967 (https://www.ncbi.nlm.nih.gov/pubmed/10
075967).
16. Orloff MJ, Daily PO, Orloff SL, Girard B, Orloff MS (Sep 2000). "A 27-year experience with surgical treatment of
Budd–Chiari syndrome"(http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?i
ssn=0003-4932&volume=232&issue=3&spage=340) . Ann. Surg. 232 (3): 340–52. doi:10.1097/00000658-
200009000-00006 (https://doi.org/10.1097%2F00000658-200009000-00006) . PMC 1421148 (https://www.ncbi.nlm.n
ih.gov/pmc/articles/PMC1421148). PMID 10973384 (https://www.ncbi.nlm.nih.gov/pubmed/10973384).
17. Budd–Chiari syndrome(http://www.whonamedit.com/synd.cfm/1335.html) at Who Named It?
18. Budd G (1845). On diseases of the liver. London: John Churchill. p. 135. Brit Lib. 000518193.
19. Chiari H (1898). "Erfahrungen über Infarktbildungen in der Leber des Menschen".
Zeitschrift für Heilkunde, Prague.
19: 475–512.

External links
Syndrome 10-138d.Budd–Chiari Syndromeat Merck Manual of Diagnosis Classification ICD-10: I82.0 · D
and Therapy Home Edition ICD-9-CM: 453.0 ·
OMIM: 600880 ·
MeSH: D006502 ·
DiseasesDB: 1735
External MedlinePlus:
resources 000239 ·
eMedicine:
med/2694 ped/296
radio/121 · Patient
UK: Budd–Chiari
syndrome

Retrieved from "https://en.wikipedia.org/w/index.php?title=Budd–Chiari_syndrome&oldid=854988957

"

This page was last edited on 15 August 2018, at 04:26(UTC).

Text is available under theCreative Commons Attribution-ShareAlike License ; additional terms may apply. By using this
site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of theWikimedia
Foundation, Inc., a non-profit organization.